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Abstract
Background: Admission hyperglycaemia is associated with mortality in patients with acute coronary syndrome
(ACS), but controversy exists whether hyperglycaemia uniformly affects both genders. We evaluated coronary risk
factors, gender, hyperglycaemia and their effect on hospital mortality.
Methods: 959 ACS patients (363 women and 596 men) were grouped based on glycaemia ≥ or< 200 mg/dL and
gender: men with glucose< 200 mg/dL (menG-); women with glucose< 200 mg/dL (womenG-); men with
glucose ≥ 200 mg/dL (menG+); and women with glucose ≥ 200 mg/dL (womenG+). A logistic regression analysis
compared the relation between gender and glycaemia groups and death, adjusted for coronary risk factors and
laboratory data.
Results group: menG- had lower mortality than menG + (OR = 0.172, IC95% 0.062-0.478), and womenG + (OR = 0.275,
IC95% 0.090-0.841); womenG- mortality was lower than menG + (OR = 0.230, IC95% 0.074-0.717). No difference
was found between menG + vs womenG + (p = 0.461), or womenG- vs womenG + (p = 0.110). Age (OR = 1.067,
IC95% 1.031–1.104), EF (OR = 0.942, IC95% 0.915-0.968), and serum creatinine (OR = 1.329, IC95% 1.128-1.566)
were other independent factors related to in-hospital death.
Conclusions: Death was greater in hyperglycemic men compared to lower blood glucose men and women
groups, but there was no differences between women groups in respect to glycaemia after adjustment for
coronary risk factors.
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Introduction
Acute coronary syndromes (ACS) are a set of presenta-
tions of coronary artery disease (CAD) and have in com-
mon unstable atherosclerotic coronary plaque. Unstable
angina (UA), non-ST-elevation myocardial infarction
(NSTEMI), and ST-elevation myocardial infarction
(STEMI) have differences in treatments and outcomes,
but some markers of poor prognosis are common, such
as clinical risk scores or several laboratory factors, in-
cluding C-reactive protein, hyperglycaemia, and elevated
brain natriuretic peptide type B [1,2].
Admission blood glucose (ABG) is a risk factor of
worse in-hospital and long-term prognosis in ACS [3,4],
both in diabetic and nondiabetic patients [5], but its in-
fluence on mortality can be different along time after an
acute event [6,7], and according to the diagnosis of
patients admitted to intensive care units [8]. In ACS
patients, women have more risk factors for CAD and are
older than men, so after adjustment for confounders, this
difference disappears, with the exception of STEMI
patients when women still have higher mortality than
men [9-11]. Champney et al [12] reported that at ages 50
to 70 years, women with STEMI do have an increased
adjusted mortality risk in comparison with men, but not in
other age ranges. On the other hand, different from that
observed in men, ABG had a non-uniform relationship
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with ACS mortality in women, as described by Cubbon
et al [13], who found a proportional increase in the hazard
ratio for mortality based on the interaction between sex
and ABG with an increase in glucose levels in men.
Women however did not have a greater risk of mortality
at levels of glucose >11.1 mmol/L (200 mg/dL).
This study evaluated the influence of ABG on hospital
mortality in ACS and its subgroups of presentations, in
particular whether this influence occurs in women in the
same way that it occurs in men.
Methods
Study design and population
Patients with ACS admitted consecutively between January
2004 and April 2007 to an urban academic cardiology
emergency single-center in São Paulo, Brazil, were pro-
spectively evaluated. The Ethics Committee of the hospital
approved this study and written informed consent was
obtained from all participants. Baseline clinical and admis-
sion laboratory characteristics, CAD risk factors, in-hospital
mortality, and treatments were observed. Ejection fraction
was obtained by echocardiography at the second day of
hospital stay. A total of 1304 ACS patients were included,
and a subgroup of 959 patients had complete data to be
studied. Inclusion criteria were ACS hospital admission,
according to the international consensus definition, age
older than 18 years, and willing to provide written
informed consent. Exclusion criteria were incomplete la-
boratory data. A sample size of at least 118 patients, with
59 subjects per treatment group, was determined to give
80% power to detect a 6% difference in the incidence of
cardiovascular events with a 5% significance level.
Definitions and data collection
Clinical outcome was defined as death. Because 90% of
patients at our emergency department undergo angio-
graphic study in 48 hours, reinfarction or refractory an-
gina are infrequent events at hospitalization. Blood
samples were collected at admission to the emergency
department and ejection fraction was obtained at second
day of stay by echocardiography with the biplane Simp-
son's method. We selected the level of hyperglycaemia
above 200 mg/dL to separate the highest stratum seen in
the literature [13] for admission nonfasting blood
glucose.
Patients were grouped by gender and ABG below
(“moderate hyperglycaemia” = G-) or above (“higher
hyperglycaemia” =G+) 200 mg/dL: menG- =men with
glucose ≤ 200 mg/dL; womenG- = women with glucose ≤
200 mg/dL; menG + = men with glucose ≥ 200 mg/dL;
and womenG + = women with glucose ≥ 200 mg/dL. We
observed patient’s distribution in acute coronary syn-
dromes. UA was defined by hospital admission with
thoracic pain (or any equivalent) considered to be of
myocardial ischemic origin, and non ST-elevation on elec-
trocardiographic or myocardial necrosis marker changes at
first consultation. NSTEMI was defined by symptoms of
myocardial ischemic origin, myocardial necrosis marker
elevation, and no ST-elevation at first electrocardiogram in
the emergency department. STEMI was considered when
symptoms of myocardial ischemic origin and ST-elevation
segment on electrocardiogram were present [14]. ABG
was managed based on emergency physicians routine: sub-
cutaneous intermittent insulin doses until blood glucose
below 140 mg/dL, and point-of-care glucose control after
first blood glucose measurement.
Treatments were defined as medical therapy only,
when patients were not candidate to angiography or the
invasive study did not result in surgical or percutaneous
intervention, and percutaneous (angioplasty) or emer-
gency coronary surgery.
Statistical analysis
All data are described as rates and frequencies or means
with standard deviations, as appropriate. Differences in
the distribution of select characteristics between patient
groups were examined using the chi-square test and
Fisher’s exact test for categorical variables. The analysis
was performed using the Student t test for normally dis-
tributed continuous variables and the Mann–Whitney
and Kruskal-Wallis tests for nonparametric variables.
General linear models analyzed the hierarchical differ-
ences of 3 groups, instead of ANOVA of the NPAR-
WAY1 approach. We built an adjusted model in
multivariate regression to analyze the independent vari-
ables associated with in-hospital death: age, family his-
tory of CAD, prior coronary artery disease, hypertension,
smoking, diabetes, categorical admission blood glucose
< or ≥ 200 mg/dL, gender, ejection fraction and serum
creatinine. This analysis was done for all ACS patients
and for AU, NSTEMI, and STEMI patients. In ACS ana-
lysis, we added type of ACS presentation to the logistic
model. Sex and categorical blood glucose were analyzed
as a specific subgroup in the logistic model. We per-
formed analysis by the stepwise approach, and variables
with p value ≤ 0.10 were included in the model. Alterna-
tively, we performed an interaction analysis of gender,
categorical admission blood glucose< or ≥ 200 mg/dL
and type of ACS presentation. Two-sided p values< 0.05
were considered statistically significant. All statistical
analyses were performed using SAS software version 9.2
for Windows (SAS Institute Inc., Cary, NC, USA).
Results
Table 1 shows a comparison between types of ACS.
Proportion of males increased from UA to NSTEMI
(53.9% vs 63.2%, p = 0.010), UA to STEMI (53.9% vs
71.7%, p< 0.001), and NSTEMI to STEMI (63.2% vs
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71.7%, p = 0.035). STEMI patients were younger than
NSTEMI (p< 0.001), had lower prior coronary artery
disease than NSTEMI or UA (p< 0.001), hypertension (p
< 0.001), dyslipidemia (p< 0.001), diabetes (p = 0.003),
total cholesterol (p = 0.009), ejection fraction (p< 0.001 in
comparison with UA); more of them were current smokers
(p< 0.001) than UA or NSTEMI patients.
Of all patients (959), men totaled 596 and women 363
(UA 304, NSTEMI 443, and STEMI 212 patients). In
STEMI patients, only 12 were treated with thrombolytic
drugs and 200 with primary angioplasty. Table 2 presents
clinical and demographic patient characteristics of all
ACS, UA, NSTEMI and STEMI patients, grouped by
ABG< or ≥ 200 mg/dL and gender. Univariate analysis
showed that higher ABG patients were older (p< 0.001),
had more hypertension (p< 0.001), diabetes (p< 0.001),
dyslipidemia (p = 0.002), higher mortality (p< 0.001) and
length of stay (p = 0.003), less smoking (p = 0.008) and
lower hemoglobin levels (p< 0.001), needed more surgi-
cal interventions (p = 0.046), and fewer percutaneous
coronary interventions (p = 0.038). Men had higher
troponin (p = 0.003) and hemoglobin levels (p< 0.001),
but lower total cholesterol (p< 0.001) and ejection fraction
(p< 0.001) than women had. In unstable angina, higher
ABG patients had more prior CAD (p = 0.013), hyperten-
sion (p = 0.019), and diabetes (p< 0.001). In NSTEMI,
higher ABG patients were older (p = 0.006), had more
hypertension (p = 0.026), diabetes (p< 0.001), higher
length of stay (p = 0.002), mortality (p< 0.001), lower ejec-
tion fraction (p< 0.001), angiography (p = 0.028), and per-
cutaneous coronary intervention (p = 0.006). In STEMI,
higher ABG patients had more hypertension (p = 0.009),
diabetes (p< 0.001), mortality (p = 0.012), and less
smoking (p = 0.036).
In multivariate logistic analysis, the adjusted model
showed as independent factors related to ACS in-hospital
death, age (OR = 1.057, IC 95% 1.022 – 1.093; p = 0.001),
serum creatinine level (OR = 1.337, IC 95% 1.335 – 1.574;
p< 0.001), ejection fraction (OR = 0.943, IC 95% 0.917 –
0.970; p< 0.001), as showed in Figure 1. When interaction
between gender and categorical admission blood glucose
was adjusted by logistic model, womenG- had lower
mortality than menG + (OR 0.259, IC 95% 0.074 – 0.905;
p = 0.034), but no difference with womenG + (OR
0.312, IC 95% 0.086 – 1.130; p = 0.076). Group menG-
had lower mortality than menG + (OR 0.160, IC 95%
0.057 – 0.452; p< 0.001) or womenG + (OR 0.193, IC
95% 0.063 – 0.588; p = 0.004). There was no difference
Table 1 Univariate clinical and demographic comparison between unstable angina, non-ST elevation and ST-elevation
myocardial infarction patients
UA* NSTEMI STEMI p-value†
Patients, n (%) 304 (31.7) 443 (46.2) 212 (22.1)
Male, n (%) 164 (53.9) 280 (63.2) 152 (71.7) a, b, c
Age (years) ‡ 60.7 ± 0.4 63.3 ± 11.9 59.2 ± 12.8 a, c
Prior coronary artery disease, n (%) 198 (65.1) 239 (53.9) 70 (33.0) a, b, c
Hypertension, n (%) 258 (84.9) 365 (82.4) 146 (68.9) b, c
Current smoker, n (%) 51 (16.8) 89 (20.1) 72 (34.0) b, c
Dyslipidemia, n (%) 171 (56.2) 228 (51.5) 67 (31.6) b, c
Diabetes mellitus, n (%) 104 (34.2) 167 (37.7) 55 (25.9) c
Family history of coronary artery disease, n (%) 44 (14.5) 84 (18.9) 35 (16.5) Non-significant
Hemoglobin (g/dL) 13.7 ± 1.6 13.6 ± 1.9 14.2 ± 1.8 b, c
Serum creatinine (mg/dL) 1.2 ± 1.0 1.3 ± 1.3 1.1 ± 0.6 a
Troponin I (ng/mL) 1.3 ± 6.5 20.6 ± 34.5 56.6 ± 57.9 a, b, c
Cholesterol (mg/dL) 185.6 ± 48.3 180.5 ± 49.0 173.5 ± 44.0 b
Admission glucose (mg/dL) 126.9 ± 60.4 136.7 ± 72.1 136.4 ± 66.7 Non-significant
Ejection fraction (%)† 56.6 ± 14.0 51.2 ± 15.5 49.4 ± 12.9 a, b
Angiography, n (%) 289 (95.1) 421 (95.0) 212 (100.0) b, c
Medical therapy only, n (%) 138 (45.4) 147 (33.2) 23 (10.8) a, b, c
Percutaneous coronary intervention, n (%) 145 (47.7) 263 (59.4) 177 (83.5) a, b, c
Surgery, n (%) 21 (6.9) 35 (7.9) 14 (6.6) Non-significant
Length of stay (days) 4.6 ± 8.1 7.3 ± 12.3 4.8 ± 5.8 a, c
Mortality, n (%) 5 (1.6) 22 (5.0) 8 (3.8) a
*UA = unstable angina; NSTEMI = non-ST elevation myocardial infarction; STEMI = ST elevation myocardial infarction; †p-value: a = UA versus NSTEMI significant; b =
UA versus STEMI significant; c = NSTEMI versus STEMI significant; ‡continuous variables are shown as mean (standard deviation), and categorical variables are
shown as number (percentage).
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Table 2 Clinical and demographic characteristics of acute coronary syndrome, unstable angina, non-ST elevation, and
ST-elevation myocardial infarction patients, grouped by gender and glycaemia glucose< or ≥ 200 mg/dL
ACS* Men glucose
<200
Women glucose
<200
Men glucose
≥200
Women glucose
≥200
p ††
Patients 454 (47.3) 242 (25.2) 142 (14.8) 121 (12.6)
Age (years) † 60.1 ± 11.4 61.9 ± 11.7 63.1 ± 11.3 64.6 ± 12.9 <0.001
Prior coronary artery disease, n (%) 244 (53.7) 113 (46.7) 81 (57.0) 69 (57.0) 0,129
Hypertension, n (%) 338 (74.4) 197 (81.4) 122 (85.9) 112 (92.6) <0.001
Current smoker, n (%) 119 (26.2) 53 (21.9) 23 (16.2) 17 (14.0) 0,008
Dyslipidemia, n (%) 192 (42.3) 133 (55.0) 73 (51.4) 68 (56.2) 0,002
Diabetes mellitus, n (%) 80 (17.6) 50 (20.7) 103 (72.5) 93 (76.9) <0.001
Family history of coronary artery disease, n (%) 77 (17.0) 40 (16.5) 23 (16.2) 23 (19.0) 0,929
Hemoglobin (g/dL) 14.3 ± 1.8 13.2 ± 1.5 13.8 ± 1.9 12.9 ± 1.8 <0.001
Serum creatinine (mg/dL) 1.2 ± 0.8 1.1 ± 1.3 1.3 ± 1.0 1.3 ± 1.4 0,331
Troponin I (ng/mL) 25.4 ± 44.4 14.8 ± 32.9 25.0 ± 44.7 16.6 ± 31.8 0,003
Cholesterol (mg/dL) 175.6 ± 44.6 194.5 ± 54.3 166.5 ± 43.9 188.6 ± 43.1 <0.001
Admission glucose (mg/dL) 101.6 ± 15.8 100.0 ± 14.9 211.2 ± 67.7 229.0 ± 84.1 <0.001
Ejection fraction (%) 50.9 ± 14.2 58.2 ± 13.3 46.8 ± 14.9 51.9 ± 15.6 <0.001
Angiography, n (%) 445 (98.0) 229 (94.6) 133 (93.7) 115 (95.0) 0,036
Medical therapy only, n (%) 134 (29.5) 88 (36.4) 42 (29.6) 44 (36.4) 0,184
Percutaneous coronary intervention, n (%) 298 (65.6) 137 (56.6) 84 (59.2) 66 (54.6) 0,038
Surgery, n (%) 23 (5.1) 19 (7.8) 16 (11.3) 12 (9.9) 0,046
Length of stay (days) 5.0 ± 6.6 5.7 ± 10.5 8.2 ± 16.1 7.2 ± 9.6 0,003
Mortality, n (%) 6 (1.3) 4 (1.6) 15 (10.6) 10 (8.3) <0.001
UA
Patients, n (%) 132 (43.4) 100 (32.9) 32 (10.5) 40 (13.2)
Age (years)* 59.9 ± 10.9 60.7 ± 9.6 61.6 ± 10.7 62.5 ± 10.8 0.537
Prior coronary artery disease, n (%) 91 (68.9) 55 (55.0) 27 (84.4) 25 (62.5) 0.013
Hypertension, n (%) 103 (78.0) 88 (88.0) 31 (96.9) 36 (90.0) 0.019
Current smoker, n (%) 25 (18.9) 16 (16.0) 6 (18.7) 4 (10.0) 0.595
Dyslipidemia, n (%) 68 (51.5) 65 (65.0) 17 (53.1) 21 (52.5) 0.197
Diabetes mellitus, n (%) 27 (20.5) 23 (23.0) 24 (75.0) 30 (75.0) <0.001
Family history of coronary artery disease, n (%) 22 (16.7) 14 (14.0) 4 (12.5) 4 (10.0) 0.734
Hemoglobin (g/dL) 14.1 ± 1.7 13.3 ± 1.4 13.9 ± 1.9 13.5 ± 1.5 0.002
Serum creatinine (mg/dL) 1.3 ± 1.2 0.9 ± 0.3 1.2 ± 0.5 1.3 ± 1.5 0.032
Troponin I (ng/mL) 1.0 ± 3.7 0.5 ± 1.6 1.2 ± 3.5 3.7 ± 16.0 0.067
Cholesterol (mg/dL) 176.3 ± 44.1 193.9 ± 46.7 178.6 ± 63.5 200.5 ± 48.9 0.017
Admission glucose (mg/dL) 99.6 (14.6) 99.3 (15.4) 222.5 (66.3) 209.5 (67.3) <0.001
Ejection fraction (%)† 56.1 ± 13.7 59.5 ± 12.8 50.7 ± 15.5 55.5 ± 15.2 0.069
Angiography, n (%) 127 (96.2) 93 (93.0) 30 (93.8) 39 (97.5) 0.593
Medical therapy only, n (%) 57 (43.2) 53 (53.0) 11 (34.4) 17 (42.5) 0.231
Percutaneous coronary intervention, n (%) 67 (50.8) 40 (40.0) 17 (53.1) 21 (52.5) 0.306
Surgery, n (%) 8 (6.1) 7 (7.0) 4 (12.5) 2 (5.0) 0.587
Length of stay (days) 4.9 ± 9.1 3.5 ± 3.2 7.3 ± 14.6 4.2 ± 4.9 0.115
Mortality, n (%) 1 (0.8) 0 4 (12.5) 0 <0.001
NSTEMI
Patients, n (%) 208 (46.9) 103 (23.3) 72 (16.3) 60 (13.5)
Age (years)* 61.2 ± 11.4 64.4 ± 12.9 65.7 ± 10.3 65.7 ± 12.5 0.006
Prior coronary artery disease, n (%) 115 (55.3) 46 (44.7) 42 (58.3) 36 (60.0) 0.159
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between gender in admission blood glucose< 200 mg/dL
(OR 0.618, IC 95% 0.0156 – 2.449; p = 0.494) or ≥
200 mg/dL (OR 1.202, IC 95% 0.470 – 3.075; p = 0.701).
When patients were separated by ACS type, in UA group
we observed that age (OR 1.168, IC 95% 1.024 – 1.332;
p = 0.021) and admission blood glucose (OR 1.019, IC 95%
1.007 – 1.031; p = 0.002) were independent factors related
to in-hospital death, whereas in NSTEMI we had age (OR
1.090, IC 95% 1.038 – 1.144; p< 0.001), ejection fraction
(OR 0.942, IC 95% 0.908 – 0.977; p = 0.001), creatinine (OR
1.357, IC 95% 1.124 – 1.639; p = 0.001), and admission
blood glucose (OR 1.005, IC 95% 1.000 – 1.009; p = 0.037).
Finally, in the STEMI group we found creatinine (OR
13.446, IC 95% 2.840 – 63.656; p = 0.001), and female
Table 2 Clinical and demographic characteristics of acute coronary syndrome, unstable angina, non-ST elevation, and
ST-elevation myocardial infarction patients, grouped by gender and glycaemia glucose< or ≥ 200 mg/dL (Continued)
Hypertension, n (%) 161 (77.4) 85 (82.5) 64 (88.9) 55 (91.7) 0.026
Current smoker, n (%) 50 (24.0) 21 (20.4) 7 (9.7) 11 (18.3) 0.073
Dyslipidemia, n (%) 97 (46.6) 53 (51.5) 41 (56.9) 37 (61.70 0.151
Diabetes mellitus, n (%) 41 (19.7) 23 (22.3) 55 (76.4) 48 (80.0) <0.001
Family history of coronary artery disease, n (%) 37 (17.8) 19 (18.4) 14 (19.4) 14 (23.3) 0.811
Hemoglobin (g/dL) 14.3 ± 1.8 13.0 ± 1.6 13.2 ± 2.0 12.7 ± 1.9 <0.001
Serum creatinine (mg/dL) 1.2 ± 0.7 1.3 ± 1.9 1.5 ± 1.4 1.4 ± 1.5 0.586
Troponin I (ng/mL) 22.6 ± 36.9 18.4 ± 34.4 19.5 ± 31.2 18.9 ± 29.7 0.734
Cholesterol (mg/dL) 178.4 ± 47.2 194.5 ± 61.2 167.1 ± 38.0 182.6 ± 39.8 0.011
Admission glucose (mg/dL) 100.8 ± 16.5 101.9 ± 14.8 202.7 ± 62.6 241.3 ± 98.7 <0.001
Ejection fraction (%)† 49.8 ± 14.9 59.3 ± 13.5 44.7 ± 14.9 49.0 ± 16.0 <0.001
Angiography, n (%) 204 (98.1) 97 (94.2) 65 (90.3) 55 (91.7) 0.028
Medical therapy only, n (%) 63 (30.3) 31 (30.1) 27 (37.5) 26 (43.3) 0.202
Percutaneous coronary intervention, n (%) 135 (64.9) 66 (64.1) 36 (50.0) 26 (43.3) 0.006
Surgery, n (%) 10 (4.8) 8 (7.8) 9 (12.5) 8 (13.3) 0.064
Length of stay (days) 5.1 ± 5.2 7.7 ± 14.5 10.7 ± 20.1 9.9 ± 12.4 0.002
Mortality, n (%) 4 (1.9) 3 (2.9) 8 (11.1) 7 (11.7) <0.001
STEMI
Patients, n (%) 114 (53.8) 39 (18.4) 38 (17.9) 21 (9.9)
Age (years)* 58.1 ± 11.9 58.7 ± 12.3 59.3 ± 12.5 65.7 ± 17.1 0.096
Prior coronary artery disease, n (%) 38 (33.3) 12 (30.8) 12 (31.6) 8 (38.1) 0.945
Hypertension, n (%) 74 (64.9) 24 (61.5) 27 (71.1) 21 (100) 0.009
Current smoker, n (%) 44 (38.6) 16 (41.0) 10 (26.3) 2 (9.5) 0.036
Dyslipidemia, n (%) 27 (23.7) 15 (38.5) 15 (39.5) 10 (47.6) 0.052
Diabetes mellitus, n (%) 12 (10.5) 4 (10.3) 24 (63.2) 15 (71.4) <0.001
Family history of coronary artery disease, n (%) 18 (15.8) 7 (17.9) 5 (13.2) 5 (23.8) 0.748
Hemoglobin (g/dL) 14.5 ± 1.8 13.2 ± 1.6 14.8 ± 1.4 12.7 ± 2.1 <0.001
Serum creatinine (mg/dL) 1.2 ± 0.4 1.1 ± 1.0 1.1 ± 0.4 1.1 ± 0.5 0.758
Troponin I (ng/mL) 58.8 ± 59.4 41.0 ± 48.7 56.1 ± 65.3 34.7 ± 47.8 0.173
Cholesterol (mg/dL) 169.3 ± 39.4 195.9 ± 56.6 156.5 ± 34.7 180.7 ± 36.1 0.001
Admission glucose (mg/dL) 105.4 ± 15.4 96.7 ± 13.6 217.9 ± 77.2 230.9 ± 60.3 <0.001
Ejection fraction (%)† 47.9 ± 12.0 51.5 ± 12.1 47.9 ± 14.6 55.4 ± 13.8 0.098
Angiography, n (%) 114 (100.0) 39 (100.0) 38 (100.0) 21 (100.0) 1.000
Medical therapy only, n (%) 14 (12.3) 4 (10.3) 4 (10.5) 1 (4.8) 0.786
Percutaneous coronary intervention, n (%) 96 (84.2) 31 (79.5) 31 (81.6) 19 (90.5) 0.719
Surgery, n (%) 5 (4.4) 4 (10.3) 3 (7.9) 2 (9.5) 0.543
Length of stay (days) 4.6 ± 5.3 5.9 ± 9.2 4.2 ± 3.4 4.9 ± 2.8 0.546
Mortality, n (%) 1 (0.9) 1 (2.6) 3 (7.9) 3 (14.3) 0.012
*ACS = acute coronary syndrome; UA = unstable angina; NSTEMI = non-ST elevation myocardial infarction; STEMI = ST elevation myocardial infarction; †continuous
variables are shown as mean (standard deviation), and categorical variables are shown as number (percentage); †† p-values refers to four-groups comparisons.
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gender (OR 0.147, IC 95% 0.024 – 0.886; p = 0.036 for men
versus women) as independent risks for death, as showed
in Table 3.
In interaction analysis, multivariate logistic analysis
model showed age (OR 1.060, IC 95% 1.025 - 1.096;
p< 0.001), ejection fraction (OR 0.944, IC 95% 0.918
- 0.971; p< 0.001), serum creatinine (OR 1.356, IC 95%
1.151 - 1.598; p< 0.001) and interaction ABG< 200 mg/dL
in male gender (OR 0.171, IC 95% 0.061 - 0.478; p = 0.017
in comparison to ABG ≥ 200 mg/dL). In female gender,
categorical blood glucose< or ≥ 200 mg/dL had no dif-
ference (OR 0.321, IC 95% 0.090 - 1.151; p = 0.078).
Figure 2 shows interaction between gender and categor-
ical blood glucose group.
Discussion
The results of this study show that ABG influences men’s
in-hospital mortality from ACS, but this effect was not
observed in women when patients of the same gender
and different degrees of ABG were compared. According
to ACS type of presentation, ABG was an independent
factor related to in-hospital mortality in UA and
NSTEMI, but not with STEMI in this study population.
In fact, differences between diagnostic categories can exist,
like that found in the Falciglia et al study [8], a significant
association between hyperglycaemia and adjusted mortality
was seen in unstable angina, acute myocardial infarction,
congestive heart failure, arrhythmia, ischemic and
hemorrhagic stroke, gastrointestinal bleeding, acute renal
failure, pneumonia, pulmonary embolism and sepsis, but
not in patients with chronic obstructive pulmonary disease,
hepatic failure, and gastrointestinal neoplasm, or those ad-
mitted to the intensive care unit after surgery for coronary
artery bypass graft, peripheral vascular disease, and hip
fracture. But in our study, ABG was not an independent
factor in STEMI, and this is different from other studies
[4,7]. Lower age of STEMI patients in our study could ex-
plain both the similarity in mortality between STEMI and
NSTEMI groups and the absence of the influence of glu-
cose on STEMI mortality.
Several hypotheses have been raised to explain the role
of hyperglycaemia in the worse prognosis in ACS. First,
ABG could reflect uncontrolled or undiagnosed diabetes
and a more advanced atherosclerosis. To justify this point
of view, there is an association of ABG with elevation of
Table 3 Odds ratio of in-hospital adjusted mortality for
unstable angina, non-ST elevation myocardial infarction,
and ST elevation myocardial infarction
UA* Odds Ratio Inferior limit
95% IC
Superior limit
95% IC
p
Age 1.168 1.024 1.332 0.021
Admission blood
glucose
1.019 1.007 1.031 0.002
NSTEMI
Age 1.090 1.038 1.144 <0.001
Ejection fraction 0.942 0.908 0.977 0.001
Creatinine 1.357 1.124 1.639 0.001
Admission blood
glucose
1.005 1.000 1.009 0.037
STEMI
Ejection fraction 0.939 0.878 1.005 0.069
Creatinine 13.446 2.840 63.656 0.001
Men vs Women 0.147 0.024 0.886 0.036
* UA = unstable angina; NSTEMI = non-ST elevation myocardial infarction;
STEMI = ST elevation myocardial infarction; IC = interval of confidence.
Figure 1 Odds ratio of in-hospital adjusted mortality of groups gender and hyperglycaemia; menG- =men with moderate
hyperglycaemia (< 200 mg/dL); womenG- =Women with moderate hyperglycaemia (< 200 mg/dL); menG + = Men with higher
hyperglycaemia (≥ 200 mg/dL); womenG + = Women with higher hyperglycaemia (≥ 200 mg/dL).
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hemoglobin A1C in these patients [15,16]. Second, ABG is
a common acute adrenergic signal of stress and is present
in myocardial infarction [17], as well as other severe acute
illnesses [8], whereas increased catecholamine levels re-
sult in decreased insulin secretion and increased insulin
resistance [18]. Third, several studies show that hyper-
glycaemia could by itself be harmful to ischemic myo-
cardium. For example, acute increases in plasma glucose
levels have significant hemodynamic effects, even in
normal subjects. In one study, maintenance of plasma
glucose levels at 15.0 mmol/L (270 mg/dL) for 2 hours
in healthy subjects significantly increased mean heart
rate (+9 beats per minute; p< 0.010), systolic
(+20 mmHg; p< 0.010) and diastolic blood pressure
(+14 mmHg, p< 0.001) and plasma catecholamine
levels [19]. In another study of flow-mediated endothe-
lium-dependent vasodilatation of the brachial artery,
significant decreases were found at one and two hours
in those with impaired glucose tolerance or diabetes, but
not in control subjects [20]. Other mechanisms of cell
injury by hyperglycaemia include higher inflammatory
response, higher circulating intercellular adhesion mol-
ecule (ICAM)-1 and increased production of superoxide
radicals and other reactive oxygen species by oxidative
stress [21]. Magnetic resonance studies [22] show that
hyperglycemic or diabetic patients have greater myocar-
dial infarct size [23], leading to impaired blood nutrition
to the ischemic myocardial wall. Jensen et al [24] showed
that hyperglycaemia at admission in STEMI patients who
are successfully treated by percutaneous angioplasty is in-
dependently associated with the presence and extent of
microvascular obstruction on contrast-enhanced magnetic
resonance. Thus, microvascular obstruction as assessed by
magnetic resonance may be a mechanism that relates
ABG in acute STEMI to a worse outcome.
The results of admission blood glucose are concordant
with others hyperglycaemia and insulin resistance eva-
luations in ACS patients. Sinnaeve et al [25] showed that
both elevated fasting glucose and admission blood glu-
cose worse in-hospital and 6-month mortality in ACS
patients. Greater glucose level (fasting or admission),
higher risk of in-hospital death, congestive heart failure,
and cardiogenic shock. Su et al [26] studied glycaemic
variability determined by a continuous 72-hours glu-
cose monitoring system and the presence and severity
of coronary artery disease in patients with type 2
diabetes mellitus. They found a correlation between
mean amplitude of glycaemic excursions (difference
between peaks and nadirs of glycaemia) and Gensini
score (r = 0.277; p< 0.001), which assesses the sever-
ity of coronary artery disease: it grades narrowing of
the lumen of the coronary artery and scores it as 1
for 1-25% narrowing, 2 for 26-50% narrowing, 4 for
51-75%, 8 for 76-90%, 16 for 91-99% and 32 for a
completely occluded artery. Feinberg et al [27] com-
pared 30-day and 1-year mortality in non-diabetic
ACS patients, groups of patients with (359 patients)
and without (701 patients) metabolic syndrome cri-
teria. Hyperglycaemia increases 30-day mortality risk
only in metabolic syndrome patients, but 1-year mor-
tality was increased by hyperglycaemia in both groups
(metabolic or non-metabolic syndrome patients). Or
Figure 2 Odds ratio of in-hospital adjusted mortality of interaction between gender and hyperglycaemia.
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in impaired glucose tolerance ACS patients, long-
term mortality is higher in patients with 2 h post-
load hyperglycemia of ≥160 mg/dL, and equal to pre-
viously known diabetes [28]. Even in non diabetic
patients with acute decompensated heart failure
admissions without myocardial infarction, hypergly-
caemia increases short and long-term mortality [29],
maybe reflecting the same higher activation of the
sympathetic system. In this setting, it is interesting
the correlation of ABG with B-type brain natriuretic
factor [30], a well-known heart failure prognostic
factor.
Based on these results, how could we explain the ab-
sence of effect, or at least absence of linear effect, of hyper-
glycaemia in women’s SCA mortality? One possibility
could be women’s comparative lower inflammatory re-
sponse. Several studies show the influence of gender on in-
flammation. Schroder et al. [31] showed that women had
lower TNF and higher IL-10 levels in sepsis. Oberholzer
et al. [32] found that male trauma patients had higher IL-6
levels than women. Deshpande and colleagues [33] showed
that estradiol attenuated the LPS-induced production of
IL-1, IL-6, and TNF by macrophages and also decreased
NFκB-binding activity. But some confounder factors can
interfere in the results of studies of ACS patients. Women
ACS patients are older than men in most of trials and
databases, and older people also have higher hypergly-
caemia, insulin resistance, erythrocyte sedimentation rate
[34,35] like women. In other words, statistical adjustment
for these confounder factors could not be enough.
Female STEMI adjusted in-hospital mortality persisted
high, like other’s observations [9,10,36]. Vaccarino and
co-workers [10] studied NRMI data and showed an
increased risk in women for death even after coronary
disease risk factor adjustment, except in patients over
75 years old, perhaps related to the comparative delay in
hospital arrival, delay in diagnosis, and lower probability
of receiving thrombolytic therapy. But 10 years later [12],
the same group found that at ages 50 to 70 the higher
adjusted mortality in women persisted, but not at other
ages. So, they hypothesized that this was the result of
greater awareness of heart disease in younger women in
recent years or improved diagnosis or treatment of acute
coronary syndromes [11]. This improvement in women’s
cardiovascular mortality was observed in a study of a
Brazilian population [37].
Study limitations
This study assesses urban Brazilian ACS patients at a
specialized cardiology center. Of STEMI patients, only
12 were treated with thrombolytics drugs, a situation not
present in nonspecialized centers. We did not evaluate
long-term outcomes, or assess risk scores like GRACE or
TIMI.
Conclusions
We conclude that age and ABG were independent risk
factors for death in UA; age, lower ejection fraction,
higher creatinine and ABG were independent risk factors
for death in NSTEMI; and lower ejection fraction, higher
creatinine and female gender were independent risk fac-
tors for death in STEMI. In global ACS patients, ABG
influenced prognosis negatively in men, but this relation
was not found in women, when hyperglycaemia was
compared in the same gender.
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